Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story stocks' without revenue, let alone profit. But the reality is that when a company ...
Antares Pharma (ATRS): Q3 EPS of -$0.04 in-line. Revenue of $11.09M (+68.8% Y/Y) beats by $1.24M. Press Release ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback